Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Apr;21(4):425–429. doi: 10.1111/j.1365-2125.1986.tb05217.x

Prolonged midazolam elimination half-life.

J W Dundee, P S Collier, R J Carlisle, K W Harper
PMCID: PMC1400931  PMID: 2939863

Abstract

The pharmacokinetics of a fixed dose of midazolam (0.3 mg kg-1 i.v.) were studied in detail in 115 healthy patients or volunteers and nine were found with a prolonged elimination half-life. A further 102 patients had an abbreviated pharmacokinetic study, of whom five showed a similar abnormality. Defective hepatic metabolism of midazolam may be a factor in the aetiology of what appears to be a true phenomenon, occurring in 6% of over 200 fit subjects given a standard dose of the drug.

Full text

PDF
425

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allonen H., Ziegler G., Klotz U. Midazolam kinetics. Clin Pharmacol Ther. 1981 Nov;30(5):653–661. doi: 10.1038/clpt.1981.217. [DOI] [PubMed] [Google Scholar]
  2. Dundee J. W., Halliday N. J., Harper K. W., Brogden R. N. Midazolam. A review of its pharmacological properties and therapeutic use. Drugs. 1984 Dec;28(6):519–543. doi: 10.2165/00003495-198428060-00002. [DOI] [PubMed] [Google Scholar]
  3. Dundee J. W., Samuel I. O., Toner W., Howard P. J. Midazolam: a water-soluble benzodiazepine. Studies in volunteers. Anaesthesia. 1980 May;35(5):454–458. doi: 10.1111/j.1365-2044.1980.tb03821.x. [DOI] [PubMed] [Google Scholar]
  4. Eichelbaum M., Bertilsson L., Säwe J., Zekorn C. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther. 1982 Feb;31(2):184–186. doi: 10.1038/clpt.1982.29. [DOI] [PubMed] [Google Scholar]
  5. Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1982 Jan-Feb;7(1):1–22. doi: 10.2165/00003088-198207010-00001. [DOI] [PubMed] [Google Scholar]
  6. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gamble J. A., Kawar P., Dundee J. W., Moore J., Briggs L. P. Evaluation of midazolam as an intravenous induction agent. Anaesthesia. 1981 Sep;36(9):868–873. doi: 10.1111/j.1365-2044.1981.tb08859.x. [DOI] [PubMed] [Google Scholar]
  8. Harper K. W., Collier P. S., Dundee J. W., Elliott P., Halliday N. J., Lowry K. G. Age and nature of operation influence the pharmacokinetics of midazolam. Br J Anaesth. 1985 Sep;57(9):866–871. doi: 10.1093/bja/57.9.866. [DOI] [PubMed] [Google Scholar]
  9. Howard P. J., McClean E., Dundee J. W. The estimation of midazolam, a water-soluble benzodiazepine by gas liquid chromatography. Anaesthesia. 1985 Jul;40(7):664–668. doi: 10.1111/j.1365-2044.1985.tb10947.x. [DOI] [PubMed] [Google Scholar]
  10. Inaba T., Jurima M., Nakano M., Kalow W. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians. Clin Pharmacol Ther. 1984 Nov;36(5):670–676. doi: 10.1038/clpt.1984.238. [DOI] [PubMed] [Google Scholar]
  11. Inaba T., Vinks A., Otton S. V., Kalow W. Comparative pharmacogenetics of sparteine and debrisoquine. Clin Pharmacol Ther. 1983 Mar;33(3):394–399. doi: 10.1038/clpt.1983.51. [DOI] [PubMed] [Google Scholar]
  12. Sloan T. P., Mahgoub A., Lancaster R., Idle J. R., Smith R. L. Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J. 1978 Sep 2;2(6138):655–657. doi: 10.1136/bmj.2.6138.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES